Literature DB >> 27255432

Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.

Froylán Gómez-Lagunas1, Elisa Carrillo1, Luis A Pardo2, Walter Stühmer2.   

Abstract

Several reports credit mibefradil with tumor suppressing properties arising from its known inhibition of Ca2+ currents. Given that mibefradil (Mb) is also known to inhibit K+ channels, we decided to study the interaction between this organic compound and the tumor-related Kv10.1 channel. Here we report that Mb modulates the gating of Kv10.1. Mb induces an apparent inactivation from both open and early closed states where the channels dwell at hyperpolarized potentials. Additionally, Mb accelerates the kinetics of current activation, in a manner that depends on initial conditions. Our observations suggest that Mb binds to the voltage sensor domain of Kv10.1 channels, thereby modifying the gating of the channels in a way that in some, but not all, aspects opposes to the gating effects exerted by divalent cations. J. Cell. Physiol. 232: 2019-2032, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27255432     DOI: 10.1002/jcp.25448

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Mibefradil inhibition of the Cole-Moore shift and K+-conductance of the tumor-related Kv10.1 channel.

Authors:  F Gómez-Lagunas; C Barriga-Montoya
Journal:  Channels (Austin)       Date:  2017-06-26       Impact factor: 2.581

2.  Correction to: Inhibition of the K+ conductance and Cole-Moore shift of the oncogenic Kv10.1 channel by amiodarone.

Authors:  C Barriga-Montoya; A Huanosta-Gutiérrez; A Reyes-Vaca; A Hernández-Cruz; A Picones; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2018-06       Impact factor: 3.657

3.  Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface.

Authors:  Pengyun Li; Hussein N Rubaiy; Gui-Lan Chen; Thomas Hallett; Nawel Zaibi; Bo Zeng; Rahul Saurabh; Shang-Zhong Xu
Journal:  Br J Pharmacol       Date:  2019-08-19       Impact factor: 8.739

4.  Inhibition of the K+ conductance and Cole-Moore shift of the oncogenic Kv10.1 channel by amiodarone.

Authors:  C Barriga-Montoya; A Huanosta-Gutiérrez; A Reyes-Vaca; A Hernández-Cruz; A Picones; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2017-12-07       Impact factor: 3.657

5.  Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.

Authors:  T A Meléndez; A Huanosta-Gutiérrez; C Barriga-Montoya; M González-Andrade; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2020-01-02       Impact factor: 3.657

6.  Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1.

Authors:  Lien Moreels; Chinmay Bhat; Manuela Voráčová; Steve Peigneur; Hannah Goovaerts; Eero Mäki-Lohiluoma; Farrah Zahed; Luis A Pardo; Jari Yli-Kauhaluoma; Paula Kiuru; Jan Tytgat
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

7.  Mibefradil alters intracellular calcium concentration by activation of phospholipase C and IP3 receptor function.

Authors:  Guilherme H Souza Bomfim; Erna Mitaishvili; Talita Ferreira Aguiar; Rodrigo S Lacruz
Journal:  Mol Biomed       Date:  2021-04-30

8.  APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1.

Authors:  Lien Moreels; Steve Peigneur; Diogo T Galan; Edwin De Pauw; Lászlo Béress; Etienne Waelkens; Luis A Pardo; Loïc Quinton; Jan Tytgat
Journal:  Mar Drugs       Date:  2017-09-13       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.